Other associated cancers include lymphomas and solid tumors. Chronic myeloproliferative disorders have also been reported in association. Non-cancerous associated conditions, include infection, tuberculosis, drugs, sickle cell disease, disseminated intravascular coagulation, hemolytic-uremic syndrome, antiphospholipid syndrome, and hyperparathyroidism.
In some cases, the cause of bone marrow necrosis cannot be determined.
Research helps us better understand diseases and can lead to advances in diagnosis and treatment. This section provides resources to help you learn about medical research and ways to get involved.
Nonprofit support and advocacy groups bring together patients, families, medical professionals, and researchers. These groups often raise awareness, provide support, and develop patient-centered information. Many are the driving force behind research for better treatments and possible cures. They can direct people to research, resources, and services. Many groups also have experts who serve as medical advisors. Visit their website or contact them to learn about the services they offer. Inclusion on this list is not an endorsement by GARD. Suggest an organization to add.
These resources provide more information about this condition or associated symptoms. The in-depth resources contain medical and scientific language that may be hard to understand. You may want to review these resources with a medical professional.
Ethical and Regulatory Aspects of the Procurement of Cell Products from Healthy Minors on Research Protocols: Protecting Minors in the Context of Potentially Life-Saving Clinical Research Friday, March 13, 2015
Location: NIH Natcher Conference Center, Bethesda, MD
The primary goal is to establish a set of guidelines to use when evaluating the role of a minor hematopoietic stem cell donor on a research protocol, as it relates to the Federal regulations governing pediatric research. Secondary goals include identifying areas of controversy in the context of minor donors and federal regulations and design actions plans to potentially implement change in the federal regulations.
Contact: Terry J. Fry, M.D.,(301) 402-0215,email@example.com
Co-funding Institute(s): National Cancer Institute, Office of Rare Diseases Research